143 related articles for article (PubMed ID: 35118877)
1. The interplay between pharmacogenetics, concomitant drugs and blood levels of amitriptyline and its main metabolites.
Mifsud Buhagiar L; Casha M; Grech A; Serracino Inglott A; LaFerla G
Per Med; 2022 Mar; 19(2):113-123. PubMed ID: 35118877
[TBL] [Abstract][Full Text] [Related]
2. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy.
Steimer W; Zöpf K; von Amelunxen S; Pfeiffer H; Bachofer J; Popp J; Messner B; Kissling W; Leucht S
Clin Chem; 2005 Feb; 51(2):376-85. PubMed ID: 15590749
[TBL] [Abstract][Full Text] [Related]
3. Quantitative Modeling Analysis Demonstrates the Impact of CYP2C19 and CYP2D6 Genetic Polymorphisms on the Pharmacokinetics of Amitriptyline and Its Metabolite, Nortriptyline.
Koh A; Pak KC; Choi HY; Ryu S; Choi SE; Kim KS; Bae KS; Lim HS
J Clin Pharmacol; 2019 Apr; 59(4):532-540. PubMed ID: 30452773
[TBL] [Abstract][Full Text] [Related]
4. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers.
Steimer W; Zöpf K; von Amelunxen S; Pfeiffer H; Bachofer J; Popp J; Messner B; Kissling W; Leucht S
Clin Chem; 2004 Sep; 50(9):1623-33. PubMed ID: 15205367
[TBL] [Abstract][Full Text] [Related]
5. CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies.
Koski A; Sistonen J; Ojanperä I; Gergov M; Vuori E; Sajantila A
Forensic Sci Int; 2006 May; 158(2-3):177-83. PubMed ID: 16024198
[TBL] [Abstract][Full Text] [Related]
6. The impact of CYP2C19 and CYP2D6 genotypes on metabolism of amitriptyline in Japanese psychiatric patients.
Shimoda K; Someya T; Yokono A; Morita S; Hirokane G; Takahashi S; Okawa M
J Clin Psychopharmacol; 2002 Aug; 22(4):371-8. PubMed ID: 12172336
[TBL] [Abstract][Full Text] [Related]
7. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.
Hicks JK; Swen JJ; Thorn CF; Sangkuhl K; Kharasch ED; Ellingrod VL; Skaar TC; Müller DJ; Gaedigk A; Stingl JC;
Clin Pharmacol Ther; 2013 May; 93(5):402-8. PubMed ID: 23486447
[TBL] [Abstract][Full Text] [Related]
8. A Study on CYP2C19 and CYP2D6 Polymorphic Effects on Pharmacokinetics and Pharmacodynamics of Amitriptyline in Healthy Koreans.
Ryu S; Park S; Lee JH; Kim YR; Na HS; Lim HS; Choi HY; Hwang IY; Lee JG; Park ZW; Oh WY; Kim JM; Choi SE
Clin Transl Sci; 2017 Mar; 10(2):93-101. PubMed ID: 28296334
[TBL] [Abstract][Full Text] [Related]
9. The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population.
Halling J; Weihe P; Brosen K
Br J Clin Pharmacol; 2008 Jan; 65(1):134-8. PubMed ID: 17764479
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
[TBL] [Abstract][Full Text] [Related]
11. The Relevance of Integrating CYP2C19 Phenoconversion Effects into Clinical Pharmacogenetics.
Scherf-Clavel M; Weber H; Unterecker S; Frantz A; Eckert A; Reif A; Deckert J; Hahn M
Pharmacopsychiatry; 2024 Mar; 57(2):69-77. PubMed ID: 38354747
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomic testing for CYP2C19 and CYP2D6 in cyclic vomiting syndrome.
Patel M; Partovi O; Karrento K; Garacchi Z; Balasubramanian G; Venkatesan T
Neurogastroenterol Motil; 2024 Jan; 36(1):e14705. PubMed ID: 37953495
[TBL] [Abstract][Full Text] [Related]
13. Serum clomipramine and desmethylclomipramine levels in a CYP2C19 and CYP2D6 intermediate metabolizer.
Brown JT; Schneiderhan M; Eum S; Bishop JR
Pharmacogenomics; 2017 May; 18(7):601-605. PubMed ID: 28470111
[TBL] [Abstract][Full Text] [Related]
14. Effect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum concentrations of antidepressants and antipsychotics: a retrospective cohort study.
Scherf-Clavel M; Frantz A; Eckert A; Weber H; Unterecker S; Deckert J; Reif A; Hahn M
Int J Clin Pharm; 2023 Oct; 45(5):1107-1117. PubMed ID: 37166747
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the Mechanism of Prolonged Persistence of Drug Interaction between Terbinafine and Amitriptyline or Nortriptyline.
Mikami A; Hori S; Ohtani H; Sawada Y
Biol Pharm Bull; 2017; 40(7):1010-1020. PubMed ID: 28674244
[TBL] [Abstract][Full Text] [Related]
16. Use of antidepressants with pharmacogenetic prescribing guidelines in a 10-year depression cohort of adult primary care patients.
Jessel CD; Mostafa S; Potiriadis M; Everall IP; Gunn JM; Bousman CA
Pharmacogenet Genomics; 2020 Sep; 30(7):145-152. PubMed ID: 32433340
[TBL] [Abstract][Full Text] [Related]
17. Effects of Genetic Polymorphism in CYP2D6, CYP2C19, and the Organic Cation Transporter OCT1 on Amitriptyline Pharmacokinetics in Healthy Volunteers and Depressive Disorder Patients.
Matthaei J; Brockmöller J; Steimer W; Pischa K; Leucht S; Kullmann M; Jensen O; Ouethy T; Tzvetkov MV; Rafehi M
Front Pharmacol; 2021; 12():688950. PubMed ID: 34093211
[TBL] [Abstract][Full Text] [Related]
18. Correlation of inter-individual variations of amitriptyline metabolism examined in hairs with CYP2C19 and CYP2D6 polymorphisms.
Thieme D; Rolf B; Sachs H; Schmid D
Int J Legal Med; 2008 Mar; 122(2):149-55. PubMed ID: 17992535
[TBL] [Abstract][Full Text] [Related]
19. A case report of a poor metabolizer of CYP2D6 presented with unusual responses to nortriptyline medication.
Lee SY; Ki CS; Hong KS; Kim JW
J Korean Med Sci; 2004 Oct; 19(5):750-2. PubMed ID: 15483356
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
